In our study, TP53 was mutated in approximately 90% of both resistant and sensitive recurrent ovarian cancer patients and pathway analysis revealed that the TP53 signaling pathway also showed high rates of mutation in both resistant (80%) and sensitive (73%) recurrent ovarian cancer. Here, TP53 is linked to ovarian carcinoma.